CA2103276A1 - Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers - Google Patents
Novel composition of angiotensin-ii receptor antagonists and calcium channel blockersInfo
- Publication number
- CA2103276A1 CA2103276A1 CA002103276A CA2103276A CA2103276A1 CA 2103276 A1 CA2103276 A1 CA 2103276A1 CA 002103276 A CA002103276 A CA 002103276A CA 2103276 A CA2103276 A CA 2103276A CA 2103276 A1 CA2103276 A1 CA 2103276A1
- Authority
- CA
- Canada
- Prior art keywords
- tetrazol
- biphenyl
- imidazole
- methyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Novel pharmaceutical compositions containing a combination of an angiotensin-II antagonist and a calcium channel blocker such as 2-butyl-4 chloro-1-[2-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl) imidazole, and diltiazem and the use of such compositions in the treatment of hypertension and congestive heart failure.
Description
2 1 0 3 2 7 ~ PCI /~JS92/03873 NOVEL COMPOSITION OF ANGIOTENSIN-II RECEPTOR
ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS
S Summa~y of th~ Invent~n This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor-antagonist from a selected class in combination with a calcium channel blocker from a selec~ed class useful for the treatment of hypertension and for the treatment of congestive heart failure.
,"~
The selected class of angiotensin-II receptor antagonists and the selected class of calcium channel blockers essential as compone~t parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in publi~hed European Published application 0 324 377 the disclosure of which is incorporated herein by reference.
Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felod~pine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
30 1 ~
e~a~ es~ iQn of the InventLQn The novel compositions of this invention contain ~`
calcium channel blocker of the group defined above in -SIJBSTITUTE SHEET
combination with an angiotensin-II receptor antagonist compound of the following formula:
~Rs ~q ~--R2 wherein R1 is CO2H; NHSO2CF3 and N - N
/~N~
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 9 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
O
CVF2v~l, where v=1-3; or -CR6;
O O
R5 is -(CH2)moR7; -~CH2)moCR7; -CH=CH-CHOR8; ~(CH~)mCR6;
WO 92/2Q342 PCI/lJS92/03B73 2i~327~
-CH2NHCOR9, - ( CH2 ) mNHso2R9;
O
N -N
-CH2/~N
H ; or -COR~;
R6 is H, alkyl o~ 1 to 5 carbon atoms or OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 i5 Hr alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
~~ Rl0 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a phar~aceutically acceptable salt thereof.
Preferred compounds of the above formula are those in which R1 is N - N
N~
H
and R2 is H. Illustrati~e compound of this preferred scope are:
2-butyl-4-chloro-1-[(2'~(lH-tetrazol-5-yl3biphenyl-4-yl)methyl]-5-~hydroxymethyl)imidazole ?5 1 - 2-butyl-4-chloro-1-[(2'-tlH-tetrazol-5- j yl)biphenyl-4-~yl)methyl]imidazole-5-carboxylic acid SUE~ST~TUTE SHEET
W092/20~2 PCT/US92/03873 ~1~327~ 4 2 propyl-9-trifluoromethyl-1-[(2'-(lH-tetrazol-5-yl)biphenyl-4-yl~methylJimidazole-5-carboxylic acld 2 propyl-4-chloro-1-[2'-~lH-tetrazol-5-yl)biphenyl-4-yl~methyl]imidazole-5-carboxaldehyde 2 propyl-4-ethyl-1-[(2'~lH-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid 2 propyl-4-ethyl-1-[(2'-lH-tetrazol-5-yl)biphenyl-4-yl)methyl~imidazole 5-carboxaldehyde 10 2-propyl-4-pentafluoroethyl~ 2'-~lH-tetrazol-5-yl)biphenyl-4-yl)methyl~imidazole-5-carboxylic acid 2-propyl-4-chloro-1-[2'-~lH-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
The potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by admini~tering the combination of active compounds to conscious spontaneously hypertensive rats.
Rats received either orally or ~ntrav~nously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angioten~in-II
receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II
receptor antagonist. Arterial blood pressure is continuously measured directly through a carotid artery catheter and rec~rded using a pressure transducer and a , polygraph. Blood pressure level~ after treatment are compared to pretreatme~t levels.
The combination of active compounds of this in~ention are unexpectedly useful in treating hypertension. They are also of value in the management SUBSTITUTE SHEEr .
W092/20~2 PC~US92/~3873 21 ~327~
.
of acute and chronic congestive heart failure. These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathyr glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, lumi~al hyperplasia, and to minimize the atherosclerotic process.
The combinations of this invention can be administered for the treatmen~ of hypertension according -to the invention by any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or in~ra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.
The combinations of co~pounds can be administered by any conventional means available for use in con~unction with pharmaceuticals, either as individual therapeutic agents or in a combination with additional therapeutic agents. For example the combination of this I invention of an angiotensin-II antagonist and calciym channel blocker can be combined with other antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride, atenolol, bendroflumethiazide, chlorothalidone, SUBSTITUTE SHEET
W092~20~2 PCT/US92/03873 21 i3~27~ i chlorothiazide~ clonidine, cryptenamine acetates and cryptenamine tannates, deserpidine, diazoxide, guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate hydrochloride, minoxidil, pargyline hydrochlor~de, polythiazide, prazosin, propranolol, ~L~Qlfia ~er~entina, rescinnamine, reserpine, sodium nitroprusside, spironolactone, timolol maleate, trichlormethiazide, trimethophan camsylate, benzthiazide, quinethazone, tiorynafan, triamterene, ~_. acetazolamide, aminophyll~ne, cyclothiazide, ethacrynic acid, furosemide! merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the l~ke.
The combinations of active oompounds can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
For the purpose of this disclosurer a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
Pharmaceutical compositions of the invention may contain from 10 to 30Q mg of the desired calcium channel blocker and 1 to lO0 mg of the angiotensin-II receptor I antagonist per unit dose one or more times daily.
The active ingredients can be administered orally :
in solid dosage forms, such as capsules, tablets, and powders, or in l~quid dosage forms, such as elixirs SUBSTITUTE SHEET
W092~20342 PCT/US~2~03873 21~327~
syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosag~ forms.
Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compres3ed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
Compressed tablets can be sugar coated or film coated to mask any unplea~ant taste and protect the tablet from . the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA.
In addition, parenteral solutions can contain , preservatives, such as benzàlkonium chloride, methyl- or propylparaben, and~chlorobutanol.
Suitable pharmaceutical carriers are described in ~ , A. Osol, a standard reference text in this field.
SUBSTITUTE SHEET
W092/20~2 PCT/US92/03B73 ~1~327~ ~
Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as fQllOWS:
~ ~Ls~l~a A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulosers~lnd 6 milligrams magnesium stearate.
A mixture of active ingredients in a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingred~ents. The capsules are washed and dried.
~ Y~a A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
Appropriate coatings may be applied to increase palatability or delay absorption.
;
Tniecta~le A parenteral composition suitable for administration by injection is prepared by stirring 1.5%
by weight of active ingredients in 10% by volume SUBSTITUTE SHEET
W092/20342 PCT/US~2/03873 ~ 1 ~ 3 2 7 fi propylene glycol. The solution is made to volume with water for injection and sterilized.
~a~
An aqueous suspension is prepared for oral administration so that each 5 milliliters con~ain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbltol solution, U.S.P~, and 0.025 milliliters of vanill~n.
SUBSTITUTE SHEET
ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS
S Summa~y of th~ Invent~n This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor-antagonist from a selected class in combination with a calcium channel blocker from a selec~ed class useful for the treatment of hypertension and for the treatment of congestive heart failure.
,"~
The selected class of angiotensin-II receptor antagonists and the selected class of calcium channel blockers essential as compone~t parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in publi~hed European Published application 0 324 377 the disclosure of which is incorporated herein by reference.
Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felod~pine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
30 1 ~
e~a~ es~ iQn of the InventLQn The novel compositions of this invention contain ~`
calcium channel blocker of the group defined above in -SIJBSTITUTE SHEET
combination with an angiotensin-II receptor antagonist compound of the following formula:
~Rs ~q ~--R2 wherein R1 is CO2H; NHSO2CF3 and N - N
/~N~
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 9 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
O
CVF2v~l, where v=1-3; or -CR6;
O O
R5 is -(CH2)moR7; -~CH2)moCR7; -CH=CH-CHOR8; ~(CH~)mCR6;
WO 92/2Q342 PCI/lJS92/03B73 2i~327~
-CH2NHCOR9, - ( CH2 ) mNHso2R9;
O
N -N
-CH2/~N
H ; or -COR~;
R6 is H, alkyl o~ 1 to 5 carbon atoms or OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 i5 Hr alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
~~ Rl0 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a phar~aceutically acceptable salt thereof.
Preferred compounds of the above formula are those in which R1 is N - N
N~
H
and R2 is H. Illustrati~e compound of this preferred scope are:
2-butyl-4-chloro-1-[(2'~(lH-tetrazol-5-yl3biphenyl-4-yl)methyl]-5-~hydroxymethyl)imidazole ?5 1 - 2-butyl-4-chloro-1-[(2'-tlH-tetrazol-5- j yl)biphenyl-4-~yl)methyl]imidazole-5-carboxylic acid SUE~ST~TUTE SHEET
W092/20~2 PCT/US92/03873 ~1~327~ 4 2 propyl-9-trifluoromethyl-1-[(2'-(lH-tetrazol-5-yl)biphenyl-4-yl~methylJimidazole-5-carboxylic acld 2 propyl-4-chloro-1-[2'-~lH-tetrazol-5-yl)biphenyl-4-yl~methyl]imidazole-5-carboxaldehyde 2 propyl-4-ethyl-1-[(2'~lH-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid 2 propyl-4-ethyl-1-[(2'-lH-tetrazol-5-yl)biphenyl-4-yl)methyl~imidazole 5-carboxaldehyde 10 2-propyl-4-pentafluoroethyl~ 2'-~lH-tetrazol-5-yl)biphenyl-4-yl)methyl~imidazole-5-carboxylic acid 2-propyl-4-chloro-1-[2'-~lH-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
The potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by admini~tering the combination of active compounds to conscious spontaneously hypertensive rats.
Rats received either orally or ~ntrav~nously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angioten~in-II
receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II
receptor antagonist. Arterial blood pressure is continuously measured directly through a carotid artery catheter and rec~rded using a pressure transducer and a , polygraph. Blood pressure level~ after treatment are compared to pretreatme~t levels.
The combination of active compounds of this in~ention are unexpectedly useful in treating hypertension. They are also of value in the management SUBSTITUTE SHEEr .
W092/20~2 PC~US92/~3873 21 ~327~
.
of acute and chronic congestive heart failure. These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathyr glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, lumi~al hyperplasia, and to minimize the atherosclerotic process.
The combinations of this invention can be administered for the treatmen~ of hypertension according -to the invention by any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or in~ra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.
The combinations of co~pounds can be administered by any conventional means available for use in con~unction with pharmaceuticals, either as individual therapeutic agents or in a combination with additional therapeutic agents. For example the combination of this I invention of an angiotensin-II antagonist and calciym channel blocker can be combined with other antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride, atenolol, bendroflumethiazide, chlorothalidone, SUBSTITUTE SHEET
W092~20~2 PCT/US92/03873 21 i3~27~ i chlorothiazide~ clonidine, cryptenamine acetates and cryptenamine tannates, deserpidine, diazoxide, guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate hydrochloride, minoxidil, pargyline hydrochlor~de, polythiazide, prazosin, propranolol, ~L~Qlfia ~er~entina, rescinnamine, reserpine, sodium nitroprusside, spironolactone, timolol maleate, trichlormethiazide, trimethophan camsylate, benzthiazide, quinethazone, tiorynafan, triamterene, ~_. acetazolamide, aminophyll~ne, cyclothiazide, ethacrynic acid, furosemide! merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the l~ke.
The combinations of active oompounds can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
For the purpose of this disclosurer a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
Pharmaceutical compositions of the invention may contain from 10 to 30Q mg of the desired calcium channel blocker and 1 to lO0 mg of the angiotensin-II receptor I antagonist per unit dose one or more times daily.
The active ingredients can be administered orally :
in solid dosage forms, such as capsules, tablets, and powders, or in l~quid dosage forms, such as elixirs SUBSTITUTE SHEET
W092~20342 PCT/US~2~03873 21~327~
syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosag~ forms.
Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compres3ed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
Compressed tablets can be sugar coated or film coated to mask any unplea~ant taste and protect the tablet from . the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA.
In addition, parenteral solutions can contain , preservatives, such as benzàlkonium chloride, methyl- or propylparaben, and~chlorobutanol.
Suitable pharmaceutical carriers are described in ~ , A. Osol, a standard reference text in this field.
SUBSTITUTE SHEET
W092/20~2 PCT/US92/03B73 ~1~327~ ~
Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as fQllOWS:
~ ~Ls~l~a A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulosers~lnd 6 milligrams magnesium stearate.
A mixture of active ingredients in a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingred~ents. The capsules are washed and dried.
~ Y~a A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
Appropriate coatings may be applied to increase palatability or delay absorption.
;
Tniecta~le A parenteral composition suitable for administration by injection is prepared by stirring 1.5%
by weight of active ingredients in 10% by volume SUBSTITUTE SHEET
W092/20342 PCT/US~2/03873 ~ 1 ~ 3 2 7 fi propylene glycol. The solution is made to volume with water for injection and sterilized.
~a~
An aqueous suspension is prepared for oral administration so that each 5 milliliters con~ain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbltol solution, U.S.P~, and 0.025 milliliters of vanill~n.
SUBSTITUTE SHEET
Claims (10)
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a combination of an angiotensin-II receptor antagonist compound of the formula:
wherein R1 is CO2H; NHSO2CF3 and ;
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
CVF2v+1, where v=1-3; or -?R6;
R5 is -(CH2)mOR7; -(CH2)mO?R7; ; -(CH2)m?R6;
-CH2NH?OR9; -(CH2)mNHSO2R9;
; or -COR6;
R6 is H, alkyl of 1 to 5 carbon atoms ox OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
R10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a pharmaceutically acceptable salt thereof and a calcium channel blocker compound selected from the group consisting of: diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
wherein R1 is CO2H; NHSO2CF3 and ;
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
CVF2v+1, where v=1-3; or -?R6;
R5 is -(CH2)mOR7; -(CH2)mO?R7; ; -(CH2)m?R6;
-CH2NH?OR9; -(CH2)mNHSO2R9;
; or -COR6;
R6 is H, alkyl of 1 to 5 carbon atoms ox OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
R10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a pharmaceutically acceptable salt thereof and a calcium channel blocker compound selected from the group consisting of: diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
2. The composition of Claim 1 wherein the angiotensin-II receptor antagonist is selected from the group consisting of:
? 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole ? 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ? 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ? 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
? 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole ? 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ? 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ? 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
3. The composition of Claim 2 wherein the calcium channel blocker is diltiazem.
4. The composition of Claim 3 wherein the angiotensin-II receptor antagonist is 2-(butyl-4-chloro-1-[2-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl) imidazole.
5. The composition of Claim 3 wherein the angiotensin-II receptor antagonist is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
6. A method of treating hypertension which comprises administering to a patient in need of such treatment a therapeutically effective amount of a composition of Claim 1.
7. The method of Claim 6 wherein the angtotensin-II
receptor antagonist is selected from the group consisting of:
? 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole ? 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid ? 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyllimidazole-5-carboxylic acid ? 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyllimidazole-5-carboxaldehyde ? 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyd ? 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid.
receptor antagonist is selected from the group consisting of:
? 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole ? 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid ? 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyllimidazole-5-carboxylic acid ? 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyllimidazole-5-carboxaldehyde ? 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyd ? 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid ? 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid.
8. The method of Claim 6 wherein the calcium channel blocker is diltiazem.
9. The method of Claim 8 wherein the angiotensin receptor antagonist is 2-butyl-4-chloro-1-[2-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole.
10. The method of Claim 8 wherein the angiotensin receptor antagonist is 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5 yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70074091A | 1991-05-15 | 1991-05-15 | |
| US07/700,740 | 1991-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2103276A1 true CA2103276A1 (en) | 1992-11-16 |
Family
ID=24814683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002103276A Abandoned CA2103276A1 (en) | 1991-05-15 | 1992-05-14 | Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0584250A1 (en) |
| JP (1) | JP2930252B2 (en) |
| AU (1) | AU664375B2 (en) |
| CA (1) | CA2103276A1 (en) |
| CZ (1) | CZ281570B6 (en) |
| IE (1) | IE921534A1 (en) |
| IL (1) | IL101858A (en) |
| MX (1) | MX9202243A (en) |
| NZ (1) | NZ242724A (en) |
| WO (1) | WO1992020342A1 (en) |
| ZA (1) | ZA923557B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3057471B2 (en) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | Agent for preventing or treating angiotensin II-mediated diseases |
| JP3883205B2 (en) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | Treatment of Atherosclerosis with Angiotensin II Receptor Blocking Imidazole |
| DE69626958T2 (en) | 1995-03-16 | 2004-03-18 | Pfizer Inc. | USE OF AMLODIPINE, ITS SALTS OR FELODIPINE IN COMBINATION WITH AN ACE INHIBITOR FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING NON-ISCHEMIC CONGESTIVE HEART INSUFFICIENCY |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| DE69936992T2 (en) | 1998-07-10 | 2008-03-06 | Novartis Pharma Ag | BLOOD HIGH PRESSURE COMBINATION OF VALSARTAN AND CALCIUM CHANNEL BLOCKER |
| US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
| US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| JP4000505B2 (en) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | Concomitant medications for treating glaucoma |
| GB0008332D0 (en) * | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
| WO2001082858A2 (en) * | 2000-05-04 | 2001-11-08 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| EP3045174A1 (en) * | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607004B1 (en) * | 1986-11-20 | 1990-06-01 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
| EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
-
1992
- 1992-05-13 NZ NZ242724A patent/NZ242724A/en not_active IP Right Cessation
- 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
- 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
- 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
- 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
- 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
- 1992-05-14 JP JP5500110A patent/JP2930252B2/en not_active Expired - Lifetime
- 1992-05-14 CZ CS932351A patent/CZ281570B6/en not_active IP Right Cessation
- 1992-05-14 MX MX9202243A patent/MX9202243A/en unknown
- 1992-05-15 ZA ZA923557A patent/ZA923557B/en unknown
- 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ281570B6 (en) | 1996-11-13 |
| AU2026992A (en) | 1992-12-30 |
| JPH06508128A (en) | 1994-09-14 |
| AU664375B2 (en) | 1995-11-16 |
| IL101858A (en) | 1996-08-04 |
| NZ242724A (en) | 1994-09-27 |
| JP2930252B2 (en) | 1999-08-03 |
| WO1992020342A1 (en) | 1992-11-26 |
| MX9202243A (en) | 1992-11-01 |
| EP0584250A1 (en) | 1994-03-02 |
| EP0584250A4 (en) | 1994-03-30 |
| ZA923557B (en) | 1993-11-15 |
| IE921534A1 (en) | 1992-11-18 |
| IL101858A0 (en) | 1992-12-30 |
| CZ235193A3 (en) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2103276A1 (en) | Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers | |
| EP0565634B1 (en) | Angiotensin ii receptor blocking compositions | |
| US5958961A (en) | Pharmaceutical composition for angiotensin II-mediated diseases | |
| US5492904A (en) | Composition of angiotensin-II receptor antagonists and calcium channel blockers | |
| EP0628313B1 (en) | Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension | |
| KR910007927A (en) | Condensed imidazole derivatives and preparation methods thereof | |
| HU219404B (en) | Process for producing pharmaceutical compositions containing angiotenzin-ii-receptor-blocking compounds for treating cardial and vascular hypertrofie and/or hyperplasy | |
| US20030181500A1 (en) | Medicinal compositions for the prevention or treatment of cardiac failure | |
| JPH11228410A (en) | Chronic renal insufficiency therapeutic agent comprising imidazole angiotensin-ii receptor antagonist | |
| IL98794A (en) | 4-alkyl-2-propyl-1-[(2'-(1h-tetrazol-5-yl) biphenyl-4-yl)-methyl]-imidazole derivatives and pharmaceutical compositions containing them | |
| CA2379666C (en) | Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof | |
| JP3057471B2 (en) | Agent for preventing or treating angiotensin II-mediated diseases | |
| JPH02235822A (en) | Composition for treatment of drug addition | |
| SK78994A3 (en) | Optic hypotensive agent and method of its preparation | |
| EP1243261B1 (en) | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | |
| EP0612523B1 (en) | Vascular hypertrophy suppressor | |
| KR100222627B1 (en) | Novel pharmaceutical composition of angiotensin-ii receptor antagonists and calcium channel blockers | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| JPWO2002092096A1 (en) | Antitumor agent | |
| Boero et al. | Verapamil in arterial hypertension with renal disease | |
| JPH01275529A (en) | Suppressing treatment agent of delayed motion effect | |
| JP3639982B2 (en) | Easy-to-absorbable oral pharmaceutical composition of carboxymethylidenecycloheptimidazole derivative | |
| Schoenberger | Calcium antagonists: use in hypertension evaluation of calcium antagonists in combination with diuretics. | |
| KR20010013014A (en) | Method of Treating Isolated Systolic Hypertension | |
| JPH0873352A (en) | Agent for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |